Press Releases

Press Releases

Date Title  
Oct 18, 2021 Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
-- Conference call today at 8:30 a.m. ET , 5:30 a.m. PT -- SEATTLE --(BUSINESS WIRE)--Oct. 18, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License
Oct 01, 2021 Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
SEATTLE --(BUSINESS WIRE)--Oct. 1, 2021-- Omeros Corporation  (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA’s ongoing review of the company’s Biologics License Application (BLA) for narsoplimab in the treatment of
Aug 09, 2021 Omeros Corporation Reports Second Quarter 2021 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Aug 03, 2021 Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
SEATTLE --(BUSINESS WIRE)--Aug. 3, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021 , on Monday, August 9, 2021 , after the market closes. Omeros management will host a conference call and
Jun 14, 2021 Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
-- Data on Organ Function Improvement Presented by Chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering -- SEATTLE --(BUSINESS WIRE)--Jun. 14, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab
Jun 10, 2021 Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
-- Inhibitors of PDE7 Enzymes Could Treat Nicotine Abuse -- SEATTLE --(BUSINESS WIRE)--Jun. 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as
Jun 09, 2021 Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
SEATTLE --(BUSINESS WIRE)--Jun. 9, 2021-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff
Jun 09, 2021 Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
-- Results show good safety and PK/PD profile consistent with low-dose, once-monthly subcutaneous dosing -- SEATTLE --(BUSINESS WIRE)--Jun. 9, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing
May 28, 2021 Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
-- Study Patients Comprise Second Cohort from Bergamo, Italy -- SEATTLE --(BUSINESS WIRE)--May 28, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market
May 20, 2021 Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
-- PDUFA Date is October 17, 2021 -- SEATTLE --(BUSINESS WIRE)--May 20, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
May 13, 2021 Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
SEATTLE --(BUSINESS WIRE)--May 13, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an
May 10, 2021 Omeros Corporation Reports First Quarter 2021 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
May 05, 2021 Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
SEATTLE --(BUSINESS WIRE)--May 5, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021 , on Monday, May 10, 2021 , after the market closes. Omeros management will host a conference call and
May 04, 2021 Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
SEATTLE --(BUSINESS WIRE)--May 4, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention ( CDC ) has approved an International Classification of Diseases (ICD-10) diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated
Mar 23, 2021 Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients -- SEATTLE & SAN FRANCISCO --(BUSINESS WIRE)--Mar. 23, 2021-- Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of
Mar 01, 2021 Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Feb 25, 2021 Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
SEATTLE --(BUSINESS WIRE)--Feb. 25, 2021-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020 , on Monday, March 1, 2021 , after the market closes.
Jan 26, 2021 Omeros Hires Nadia Dac as Chief Commercial Officer
SEATTLE --(BUSINESS WIRE)--Jan. 26, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial
Jan 19, 2021 Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
-- FDA sets PDUFA date of July 17, 2021 -- SEATTLE --(BUSINESS WIRE)--Jan. 19, 2021-- Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy
Jan 11, 2021 Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jan. 11, 2021-- Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference